Metformin Inhibits the Urea Cycle and Reduces Putrescine Generation in Colorectal Cancer Cell Lines

• Published in: Molecules (Basel, Switzerland) Vol. 26; no. 7; p. 1990
• Main Authors: Zhang, Tao, Hu, Ling, Tang, Jia-Feng, Xu, Hang, Tian, Kuan, Wu, Meng-Na, Huang, Shi-Ying, Du, Yu-Mei, Zhou, Peng, Lu, Rui-Jin, He, Shuang, Xu, Jia-Mei, Si, Jian-Jun, Li, Jing, Chen, Di-Long, Ran, Jian-Hua
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.04.2021; MDPI
• Subjects: Ammonia; Antidiabetics; Antitumor activity; Apoptosis; Arginase; Biosynthesis; Body weight; Breast; Cancer; Carbamoyl phosphate; Cell cycle; Cell growth; Cell proliferation; Colorectal cancer; colorectal cancer (CRC); Colorectal carcinoma; Diabetes mellitus (non-insulin dependent); Enzymes; Gene expression; human colorectal cancer HCT116 cell line; Kinases; Medical prognosis; Metabolic pathways; Metabolism; Metformin; Nitrogen; Ornithine decarboxylase; p53; p53 Protein; Polyamines; proliferation; Protein kinase; Proteins; Putrescine; Spermidine; Spermine; Tumor cell lines; Tumorigenesis; Tumors; Urea; urea cycle; Xenografts; Xenotransplantation; human colorectal cancer HCT116 cell line; CPS1; proliferation; ARG1; metformin; colorectal cancer (CRC); urea cycle; putrescine; ODC; OTC; p53
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules26071990

The urea cycle (UC) removes the excess nitrogen and ammonia generated by nitrogen-containing compound composites or protein breakdown in the human body. Research has shown that changes in UC enzymes are not only related to tumorigenesis and tumor development but also associated with poor survival in hepatocellular, breast, and colorectal cancers (CRC), etc. Cytoplasmic ornithine, the intermediate product of the urea cycle, is a specific substrate for ornithine decarboxylase (ODC, also known as ODC1) for the production of putrescine and is required for tumor growth. Polyamines (spermidine, spermine, and their precursor putrescine) play central roles in more than half of the steps of colorectal tumorigenesis. Given the close connection between polyamines and cancer, the regulation of polyamine metabolic pathways has attracted attention regarding the mechanisms of action of chemical drugs used to prevent CRC, as the drug most widely used for treating type 2 diabetes (T2D), metformin (Met) exhibits antitumor activity against a variety of cancer cells, with a vaguely defined mechanism. In addition, the influence of metformin on the UC and putrescine generation in colorectal cancer has remained unclear. In our study, we investigated the effect of metformin on the UC and putrescine generation of CRC in vivo and in vitro and elucidated the underlying mechanisms. In nude mice bearing HCT116 tumor xenografts, the administration of metformin inhibited tumor growth without affecting body weight. In addition, metformin treatment increased the expression of monophosphate (AMP)-activated protein kinase (AMPK) and p53 in both HCT116 xenografts and colorectal cancer cell lines and decreased the expression of the urea cycle enzymes, including carbamoyl phosphate synthase 1 (CPS1), arginase 1 (ARG1), ornithine trans-carbamylase (OTC), and ODC. The putrescine levels in both HCT116 xenografts and HCT116 cells decreased after metformin treatment. These results demonstrate that metformin inhibited CRC cell proliferation via activating AMPK/p53 and that there was an association between metformin, urea cycle inhibition and a reduction in putrescine generation.